# Cencora

Type: Company (COR)

Source: GetYourBrief — https://getyourbrief.com/entity/cencora
Canonical HTML page: https://getyourbrief.com/entity/cencora

## Recent coverage (2 stories, network-wide)

### NovoCure’s $655M Revenue Signals a Shift in Direct-to-Patient Cancer Care
2026-06-28 04:07:26 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Amgen and NovoCure represent two extremes in healthcare delivery: a wholesale-dependent drug giant and a patient-centric device innovator. The comparison reveals how direct-to-patient models are reshaping oncology treatment accessibility and reimbursement dynamics.
Full story: https://gethealthbrief.com/story/novocure-direct-patient-model-healthcare-2026

### Amgen’s $36.8B Pipeline vs NovoCure’s Tumor-Fighting Tech: Which Innovator Wins?
2026-06-28 04:07:18 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Amgen brings a massive $36.8B revenue base and a broad chronic disease pipeline, while NovoCure pushes the frontier with electric‑field cancer therapy. This analysis weighs drug development scale against device‑based oncology innovation for biotech investors.
Full story: https://getbiobrief.com/story/amgen-vs-novocure-biopharma-innovation-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.